The Effect of IV Cangrelor and Oral Ticagrelor Study
Acute Coronary Syndrome (ACS), High On-treatment Platelet Reactivity (HTPR), Microvascular Obstruction (MVO)
About this trial
This is an interventional treatment trial for Acute Coronary Syndrome (ACS) focused on measuring Adenosine Diphosphate, Cardiovascular Magnetic Resonance (CMR), Index of microvascular resistance (IMR), Vasodilator stimulated phosphoprotein phosphorylation (VASP), Pharmacodynamic, Antiplatelet, Myocardial Infarction (MI), Cangrelor, Ticagrelor, Coronary artery bypass graft (CABG), Primary percutaneous coronary intervention (PPCI)
Eligibility Criteria
Inclusion Criteria:
- Patients presenting with STEMI eligible for PPCI
- Able to give verbal assent pre procedure and written consent following the procedure.
- Age ≥18 years
- No contraindication to Cangrelor or Ticagrelor
- Thienopyridine naïve
If a patient gives verbal assent but is unable to provide a written consent at a later stage due to incapacitation, presumed consent will be continued. The reasons why a patient becomes incapacitated and becomes unable to provide a written consent will be recorded during data collection.
Exclusion Criteria:
- Be unable to provide verbal assent and written consent
- Allergic to Aspirin or any of the P2Y12 antagonists in the trial
- Have pre-existing cardiogenic shock
- Previous myocardial infarction
- Have a concurrent septic or inflammatory disease e.g. rheumatoid arthritis, lupus, and pneumonia.
- Already taking a P2Y12 inhibitor
- Known bleeding diathesis
- Significant active bleeding
- History of intracranial hemorrhage
- Patients who are being treated with formal anticoagulation (Vitamin K antagonist, Factor II or Xa inhibitors) or have an indication for anticoagulation during the first four hours of the study period. Example is patients known to have atrial fibrillation, pulmonary embolism or deep vein thrombosis.
- Known severe renal dysfunction requiring renal replacement therapy.
Sites / Locations
- The Royal Wolverhampton NHS Trust
Arms of the Study
Arm 1
Arm 2
Active Comparator
Active Comparator
Oral Ticagrelor
Intravenous Cangrelor
Patients in the oral Ticagrelor arm will receive Ticagrelor at a loading dose of 180mg followed by maintenance dose of 90mg twice daily for 12 months.
Patients in the intravenous Cangrelor arm will receive Cangrelor as an initial bolus dose given as per body weight followed by an intravenous infusion for no longer than three hours, they will then switch to oral Ticagrelor given at maintenance dose of 90mg twice daily for 12 months